<DOC>
	<DOCNO>NCT02217163</DOCNO>
	<brief_summary>Patients high risk multiple myeloma short remission period reduce overall survival . Prognostic significance minimal residual disease negative remission highlight many new study . The current phase 2 study investigates combination carfilzomib together cyclophosphamide dexamethasone patient high risk multiple myeloma young transplantation eligible patient .</brief_summary>
	<brief_title>A Single Arm Study Carfilzomib Transplant Eligible High Risk Multiple Myeloma</brief_title>
	<detailed_description>Carfilzomib administer 30 minute infusion . For cycle 1 , Carfilzomib administer 20mg/m2 IV day 1 2 , follow escalation 56mg/m2 day 8,9,15 16 28 day cycle . Patients tolerate 56mg/m2 dose keep dose subsequent cycle Days 1,2,8,9,15,16 28 day cycle . Dose schedule modification intolerable side effect detail protocol . Additionally Cyclophosphamide give fix dose 500mg per week orally , along dexamethasone give day Carfilzomib administration , 30 minute 4 hour prior Carfilzomib . Patients undergo blood test weekly serum protein electrophoresis every 4 week treatment . Within completion 8 cycle treatment patient would undergo stem cell collection use chemotherapy growth factor mobilization . After completion 8 cycle treatment autologous bone marrow transplantation ( BMT ) conduct . Patients achieve stringent CR 8 cycle undergo bone marrow biopsy minimal residual disease ( MRD ) analysis flow cytometry ( MPFC ) . If MRD negativity MPFC achieve , may proceed directly autologous BMT possible , MRD positive , continue complete 8 cycle treatment proceed autologous BMT . Following bone marrow transplantation , stag investigation include blood bone marrow investigation MRD analysis MPFC . Patients achieve MRD negativity MPFC manage expectantly watch wait . Patients MRD positive stage undergo consolidation maintenance 2 year disease progression . Follow would extend till minimum 2 year completion study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Newly diagnose multiple myeloma AND Transplant eligible AND High Risk define International stag system 3 OR Deletion 17p OR Amplification 1q OR transaction 4,14 OR translocation 14,16 OR translocation 14,20 1 . Relapsed Myeloma 2 . Non Transplant eligible patient . 3 . Ig M subtype Myeloma 4 . POEMS syndrome 5 . Amyloidosis 6 . Waldenstroms Macroglobulinemia 7 . Radiation therapy extend field involve significant volume bone marrow within 21 day randomizationLimited site radiation allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>